Abbas Hussain, who was sent to China to help with the probe, said he had a "very constructive meeting" with officials from the Ministry of Public Security. GSK faces allegations of economic crimes involving 3 billion yuan ($489 million) of spurious travel and meeting expenses as well as trade in sexual favours, the ministry said last week.
"Certain senior executives of GSK China who know our systems well, appear to have acted outside of our processes and controls which breaches Chinese law," Hussain said in an emailed statement. "We have zero tolerance for any behaviour of this nature."
Separately, Peter Humphrey, founder of a Shanghai-based company that worked with the UK's largest drugmaker to organise an anti-corruption seminar, has been detained in Beijing since July 10, a spokeswoman for the Foreign Office in London said by phone. The spokeswoman, who asked to remain unidentified citing the department's policy, didn't specify whether the detention was linked to the probe into GSK.
'Local matter'
The probe may be widening, given that at least six other global drugmakers, including Merck & Co, Novartis AG, Roche Holding AG and Sanofi, used the same travel agency to make arrangements for events and conferences in the last three years, The New York Times reported, citing documents it obtained.
Sanofi and Roche on Monday confirmed they had worked with the travel agency, called Shanghai Linjiang. Both said they had stopped once the allegations of wrongdoing surfaced. AstraZeneca Plc also said on Monday police had visited its offices in Shanghai, though it believes that was related to "a local police matter focused on a sales representative".
China detained four senior GSK executives on suspicion of economic crimes, the ministry said July 15. Its finance chief in China, Steve Nechelput, has been unable to leave the country since the end of June because of the investigation, though he hasn't been arrested or questioned, Simon Steel, a GSK spokesman in London, said July 18.
GSK's executives "violated China's laws and damaged markets by engaging in bribery to raise drug prices, expand sales and reap inappropriate profits," China's Public Security Ministry said in a statement posted on its website on Monday. Hussain apologised on behalf of London-based GSK and pledged to cooperate with the investigation, the ministry said, citing a recent meeting with the executive and his colleagues.
Travel centres
GSK is reviewing how it operates in China, according to Hussain. "Savings made as a result of proposed changes to our operational model will be passed on in the form of price reductions, ensuring our medicines are more affordable to Chinese patients," he said.
The company, which made about £1 billion ($1.5 billion) of revenue in China last year, had said in June that it found "no evidence of corruption or bribery" there after a four-month internal investigation.
GSK fell as much as 1.2 per cent to 1,694 pence in London trading. The stock has gained 27 per cent so far this year.
State-owned China Central Television aired a prime-time segment on July 16 detailing how GSK executives used travel centres including Shanghai Linjiang International Travel Agency to funnel bribes to government officials, hospitals and doctors.
Liang Hong, an operations manager for GSK China and one of the executives detained, said consumers were paying 20 to 30 per cent more for drugs because of the bribery, the official Xinhua News Agency reported on July 15.
Humphrey, the British national detained in Shanghai, is the founder of risk management advisory ChinaWhys, according to the consultancy's website. ChinaWhys teamed up with GSK in 2004 to produce a seminar for the European Chamber of Commerce in Shanghai on fraud, corruption and intellectual property issues, according to the website.
The UK Foreign Office is providing consular assistance to Humphrey's family, the spokeswoman said. Calls to a mobile number for the Shanghai police press office weren't answered.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)